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ABSTRACT 
 
 
Taenia solium is a cestode that has a two-hosts life cycle. The adult tapeworm 
causes an asymptomatic disease known as taeniasis whereas the larval stage causes a 
disease called cysticercosis. In humans, the most common localization for the larvae is 
the central nervous system where it produces the neurological disorder neurocysticerco-
sis. Previous works by several research groups around the world have shown that T. so-
lium is a potentially eradicable parasite. Control programs have included treatment of 
human and pig populations with antihelmintics in conjunction with health education and 
are now considering vaccination of naïve piglets. 
The potential of a live vector vaccine system to deliver Taenia solium Tsol18, a 
proven protective antigen, to prevent transmission of cysticercosis was investigated. An 
attenuated strain of Salmonella enterica serovar Typhimurium χ9402 was used to devel-
op an oral delivery system. Tsol18 gene was cloned downstream from the β-lactamase 
signal sequence in a multicopy asd + plasmid vector pYA3620 to yield plasmid 
pYA3620/Tsol18 and then transformed into the vaccine strain. The recombinant atte-
nuated salmonella vaccine construct was stable for 50 generations and expressed 
rTsol18. Immunization of mice either with one or two doses of 109 CFU of the recombi-
nant vaccine strain carrying plasmid pYA3620/Tsol18 elicited specific antibody response 
to Salmonella self antigens and to rTsol18. Moreover, oral immunization of piglets with 
1012 CFU of the vaccine construction significantly reduced the numbers of viable cysts 
after challenged.  
 
The development of a quantitative assay to detect specific antibodies against 
Tsol18 is also presented here. The Falcon assay screening test –enzyme linked immu-
noabsorbant assay (FAST-ELISA) format was used to develop a quantitative antibody 
detection assay. We have cloned, expressed and purified rTsol18. With purified porcine 
IgGs we constructed a standard curve that can be used to quantify the immune re-
sponse. Our Fast-ELISA was able to follow the kinetics of the immune response in vac-
cinated pigs from an experimental trial.  The data we present here provides the basis for 
a safe, affordable and easy vaccine delivery system that can be used as an adjunct in 
control programs.  
 
INDEX WORDS: Taenia solium, Cysticercosis, Salmonella, Vaccine, Tsol18, Fast-
ELISA. 
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I. General Introduction  
 
Taenia solium/Cysticercosis is a highly endemic parasitic disease in developing 
countries where transmission is associated with pigs raised in close contact with humans 
and with poor hygiene and sanitary condition (Garcia and Del Brutto, 2005; Flisser et al., 
2006). Epidemiological studies carried out during the last two decades have demon-
strated that cysticercosis is highly prevalent in Cameroon, Tanzania, Zambia, Madagas-
car, India, Nepal, parts of China, Vietnam, Papua New Guinea (Irian Jaya), Mexico, Ec-
uador, Colombia and Peru among others (Flisser et al., 2003; Carabin et al., 2006). 
 
Although cysticercosis is considered an imported disease in developed countries, 
immigration, immigrant domestic workers, and international travel have increased the 
prevalence of the disease in these non-endemic areas. For example, in the United 
States cysticercosis has emerged as a common cause of seizures among immigrants 
from Mexico and other endemic area (Schantz et al., 1992; Schantz, 2006). Infections 
with the pork tapeworm are still common in developing countries and constitute a public 
health problem because they produce thousands of infective eggs for humans and pigs 
causing clinical diseases known as neurocysticercosis and cysticercosis. Immigrants 
from endemic countries carrying adult tapeworms have been shown to spread the dis-
ease to industrialized countries in recent years (Schantz et al., 1993).  
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I.1 Taenia solium life cycle 
 
Taenia solium has a complex two-host life cycle. Humans are the only natural de-
finitive host harboring the adult tapeworm whereas pigs and humans can both act as in-
termediate hosts harboring the metacestodes (Figure I.1).  After ingestion of under-
cooked pork meat infected with cysticerci, the larva evaginate, attaches to the duodenal 
wall and develop into a tapeworm (Garcia et al., 2003a). The tapeworm grows and proli-
ferates producing hundred of hermaphroditic proglottids and undergo differentiation to 
form gravid proglottids full of infective eggs (Naquira, 1999)  . 
 
 
Figure I.1 Taenia solium life cycle * 
 
 
 
* Source (Garcia et al., 2003a) 
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The eggs and distal gravid proglottids are eliminated in the feces of a human in-
fected with the adult tapeworm and can contaminate the environment. Pigs became in-
fected with cysticerci after they eat human feces with Taenia eggs. After ingestion, the 
oncosphere hatches and releases the embryo which penetrates the intestinal wall reach-
ing the general blood circulation, and presumably, are transported to different tissues, 
specially muscle were they develop into cysts (Flisser, 1986). Each egg with an oncos-
phere can develop into a larva, or metacestodes, a process which takes about 8 weeks 
(Lapage, 1974). 
 
 Humans can develop the cysts after accidental ingestion of T. solium eggs in 
contaminated food. Contact with tapeworm-infected individuals is believed to be the 
most probable mechanism for infection along with poor hygienic habits allowing for the 
contamination of hands by eggs, and thus the likelihood of contaminating food for the 
family group (Flisser, 1986; Garcia et al., 2003a) . Also, eggs that contaminate short-
term vegetables and/or water for consumption can also be ingested, particularly in areas 
with poor environmental sanitation and open air defecation. It has also been claimed; 
that intestinal retroperistaltic movements induced in T. solium carriers by any cause, 
would allow the gravid proglottids or eggs to reach the stomach, and here, the action of 
the gastric fluids release the hexacanth embryos, thus producing an internal autoinfec-
tion (Loo and Braude, 1982) .  
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I.2 History and evolution 
 
Phylogenetic analysis of Taenia species have shown that species of Taenia that 
infects humans did not form a clade and may represent two independent shifts.  The 
phylogenetic evidence also showed that African hominids that preyed on antelopes and 
other bovids were exposed to Taenia infection. These Taenia species that first infected 
humans were using hyanids, canids and felids as definitive hosts and bovids as interme-
diate ones. Therefore, it can be assumed that Taenia species became associated with 
humans 10,000 years ago wen domestication of the intermediate host occurred (Hoberg 
et al., 2001) . Furthermore, immigration of human clans from Africa to Eurasia brought 
the Taenia  ancestor along with them (Hoberg et al., 2001). 
 
Species of Taenia were among the earliest recognized parasites in human writ-
ten records. The earliest reference to tapeworms was found in the work of ancient Egyp-
tians (2000 BC). A study published in 2006 described a case of  cysticercosis on a Egyp-
tian mummy dating to the Ptolemaic period (Bruschi et al., 2006). Taenia solium was ap-
parently well known by the Greeks.  The description of “measly pork” in the History of 
Animals written by Aristotle (384-322 BC) showed that the infection of pork with tape-
worm was known to ancient Greeks. However, there is no evidence to suggest that the 
Greek physicians knew that some humans harbored cysts in the brain or suffer from epi-
leptic episodes that were associated with them (Cox, 2002; Wadia, 2002).  
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During the colonial era the European isolates were introduced to Latin America 
along with pigs (Nakao et al., 2002; Ito et al., 2003). Cysticercosis was described by Jo-
hannes Udalric Rumler in 1555; however, the connection between tapeworms and cysti-
cercosis had not been recognized at that time (Wadia, 2002).  Before the relationship 
between Taenia species and their larval stages were completely understood the cysti-
cerci were described as independent species with their own scientific names. It was not 
until 1784 when Johann Goeze recognized that the cysticerci were the larval stages of 
tapeworm (Cox, 2002). 
 
Scientific studies of Taenia species can be trace back to 17th century when Ed-
ward Tyson recognized for the first time the tapeworm head (scolex). Even though it was 
clear now that there were significant morphological differences between various species 
of tapeworms, it was not until the middle of the 19th century that the differences between 
T. solium and T. saginata were first recognized by Kuchenmeister. It was during the 
same century that, Kuchenmeister performed an experiment in which he fed under-
cooked pork containing cysticerci of T.solium to humans awaiting execution in a prison, 
and after they had been executed, he recovered the developing and adult tapeworms in 
their intestines. It was also established around this time that cysticercosis was caused by 
ingestion of T. solium eggs  (Cox, 2002).  
 
Recently, phylogenetic polymorphism was demonstrated among 13 T. solium iso-
lates from different regions around the world. PCR amplification of 2 mitochondrial 
genes: cytochrome c oxidase subunit 1 (Cox1) and cytochrome b (Cytb) showed that 
isolated from China, Irian Jaya, India and Thailand formed a single cluster whereas the 
6 
isolated strains from Peru, Mexico, Ecuador, Bolivia and Brazil together with those from 
Tanzania, Mozambique and Cameroon formed a different cluster. These polymorphism 
probed that T. solium that was introduced into Latin America had a different origin from 
the one spread in Asia (Nakao et al., 2002).  
 
I.3 Taenia solium morphology 
I.3.1 Adult tapeworm 
 
Taenia solium is a flat, segmented hermaphrodite parasite that can grow up to 
eight meters in length in the small intestine of the human host. Morphologically, 3 por-
tions can be recognized in the adult tapeworm: the head, the neck and the body or stro-
bile. The head, also known as scolex (Figure I.2) is a 1 millimeter structure that has a 
pear shape bearing four muscular suckers for fixation and has a small terminal cone 
known as rostelum. At the base of the rostelum, there is a double row of hooks which 
can number from 22 to 36 (Naquira, 1999).  
 
 
 
7 
                        
 
 
Figure I.2 Taenia solium adult tapeworm * 
     
 
A: Taenia solium scolex; B: Strobile of adult tapeworm. The size and form of the proglot-
tids change as they mature (Garcia and Del Brutto, 2000). 
* Source (Garcia et al., 2003). 
 
The neck is a poorly differentiated structure, made of germinative tissue with high 
mitotic activity located immediately posterior to the scolex, which measures 5 to 10 mil-
limeters long. It is the portion where the formation of immature proglottids starts (Naqui-
ra, 1999).  
 
The body or strobile is the longest portion of the parasite and is made up of a se-
ries of segments known as proglottids. Proglottids are covered by a tegumentary surface 
that constitutes the absorption surface through which the worm takes up metabolites 
from the host (Willms, 2008). The genital pores are located on each side of each proglot-
tid. The strobile has immature, mature and gravid proglottids. Immature proglottids are 
undifferentiated and located next to the neck. Mature proglottids are complete reproduc-
tive units with a complete set of male and female reproductive organs that may undergo 
A B 
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self or cross fertilization. Gravid proglottids are located in the posterior part of the body 
of the parasite and have a highly branched uterus filled with eggs. Gravid proglottids are 
cut off from the tapeworm body and are released with the host feces (Naquira, 1999).  
 
I.3.2 Oncosphere 
 
T. solium uterus contains multiple spherical eggs that contain the hexacanth 
embryo also known as oncosphere (Figure I.3).  T. solium eggs are composed of a cho-
rionic membrane, an embryophore, an embryophoral membrane, and two oncosphere 
membranes that surround the embryo. T. solium eggs are very resistant to common dis-
infectants and environmental conditions. They can survive in humid ground for months 
(Bowman, 1999). 
 
 
Figure I.3 Taenia solium oncosphere 
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I.3.3 Cysticercus 
 
The cysticercus is the larval stage of T. solium, called Cysticercus cellulosae by 
Rudolphi (1803) given its predilection for conjunctive tissue. Morphologically, the cysti-
cercus is a translucent vesicle full of liquid, measuring between 0.5 and 2 cm in diameter 
with an invaginated scolex. The cysticercus vesicle is surrounded by a thin layer of fibr-
ous tissues that separates it from the surrounding tissue (Lapage, 1974) (Figure I.4). 
Sometimes, depending on the location of the cyst, this morphology can vary to include 
irregular forms such as racemose. Racemose cysticercus looks like a large lobulated 
vesicle, similar to a bunch of grapes. It may measure up to 10 cm of diameter and con-
tain several milliliters of fluid and is generally observed in the ventricular cavities and in 
the cisterns located at the base of the cranium (OMS/OPS, 1993).  
 
The histological structure of the bladder wall consists of three layers and differs 
from the parenchymatous portion containing the invaginated scolex which is sealed in-
side the bladder cavity. The cysts parenchyma is composed of a complicated system of 
cells, slits, fibers and channels that permit the invagination of the scolex. The invagi-
nated scolex forms a spiral canal; the suckers are present at its end from which the ros-
telum with hooks arises (Willms, 2008).  
 
In the initial phase of the cysticercus growth, the invaginated scolex and spiral 
canal leading to it are developed in the parenchymatous portion of the elongated larval 
body. The formation of the invaginated scolex and the development of the spiral canal 
change the initially poorly differentiated bladder. The cyst attains its final shape after a 
10 
secondary developmental phase during which the anterior parenchymatous portion of 
the larval body becomes completely enveloped by the posterior part through a second-
ary growth of the bladder, giving rise to a typical cyst. In vitro, when a viable cysticercus 
is exposed to bile, the larvae evaginate a process whereby the scolex emerges from the 
vesicle. In vivo the evagination process releases the scolex into the duodenum where it 
attaches into the wall of the definitive host (Willms, 2008). 
 
 
    
 
Figure I.4 Cysticercus cellulosae 
A: Cysticercus cellulosae as seen in a heavily infected pig; B: Excised in a petri dish the 
white dot pointed with an arrow corresponds to the scolex (Garcia and Del Brutto, 2000). 
 
 
 
A B 
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I.4 Clinical importance of Taeniasis and cysticercosis 
I.4.1 Taeniasis 
 
Taeniasis (infection by an adult tapeworm) occurs only in the human host. Adult 
T. solium carriers present few or no symptom, although some patients presented abdo-
minal pain, distension, diarrhea and nausea (OMS/OPS, 1993). The association be-
tween the presences of the parasite and weight loss of the patients has not been dem-
onstrated. Thus, the general condition of the individual is not affected. Some people 
eliminate pieces of strobile in their feces.  Identification of T .solium infections becomes 
important because of the risk of cysticercosis not only for the tapeworm carrier but also 
for its surrounding environment (Garcia et al., 2003a). Frequency of autoinfection in ta-
peworm carriers is unknown, however; approximately 25% of cysticercosis patients har-
bor also the tapeworm (Dixon, 1961). 
 
I.4.2 Cysticercosis 
 
In humans, the clinical importance of the infection appears when the metaces-
tode develops in the central nervous system producing neurological disorders, or NCC. 
Although there is an active infection, the disease typically remains unrecognized during 
the early stages unless the cyst obstructs cerebral spinal fluid (CSF) circulation (Garcia 
and Del Brutto, 2000; Garcia and Del Brutto, 2005). After variable times, the cysts start 
to degenerate and produce an immune mediated inflammation, which results in clinical 
manifestation of the disease. NCC symptoms are related to number, size and localiza-
12 
tion of the parasites as well as in the severity of the host’s immune response. Late onset 
of epileptic seizures is the commonest and sometimes the only manifestation of NCC. 
Seizures occur in 50 to 80% of patients with cysts in the parenchyma or with calcifica-
tions. NCC patients can also develop intracranial hypertension and hydrocephalus as a 
consequence of the presence of cysts in the cerebral ventricles or basal cisterns of the 
brain (Garcia et al., 2003a). Even though the central nervous system is the most relevant 
clinical localization for the cysticerci they can also be found in muscle and subcutaneous 
tissue.  
 
 
 
Figure I.5  Human cysticercosis * 
    
A: Human neurocysticercosis, MRI caverns in the brain indicate the presence of viable 
cysts; B: Cysticercosis muscular localization calcified cysts on the CT. 
* Source (Garcia et al., 2004) 
 
B 
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I.5 Diagnosis and treatment 
I.5.1 Taeniasis 
 
Diagnosis of taeniasis in human faces two major problems for diagnostic. The 
first problem is the lack of sensitivity of the microscopic stool examination and the 
second one is the morphological similarities between T. solium and T. saginata eggs.  
Microscopic visualization of Taenia eggs present in stool samples was for many years 
the only available diagnostic method (Garcia et al., 2003a). The detection in stool sam-
ples of tapeworm metabolic products with antigenic capabilities has been used to pre-
pare specific polyclonal antibodies that allow the detection of coproantigens by ELISA. 
Coproantigen detection has a specificity and sensitivity of 100% and 98% respectively 
(Allan et al., 1990; Allan et al., 1992). 
 
In 1999, Wilkins et al described T. solium specific antigens to detect serum anti-
bodies using the western blot assay (Wilkins et al., 1999). The western blot showed a 
95% sensitivity and 100% specificity (Levine et al., 2004). No cross reaction with sam-
ples from patients with T. saginata or other cestode infections were reported. However, 
one samples from a neurocysticercosis patient without taeniasis tested positive (Allan et 
al., 2003). Diagnosis of taeniasis by serological examination has some advantages over 
stool sample examination methods. However, residual antibodies from previous infec-
tions or exposure might result in a false positive diagnostic (Allan et al., 2003; Ito and 
Craig, 2003). 
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During the last two decades highly specific molecular methods to detect T. so-
lium DNA in stool such as PCR and RFLP have been developed (Mayta et al., 2000; 
Nunes et al., 2003; Nunes et al., 2005; Yamasaki et al., 2005; Nunes et al., 2006; Dias 
et al., 2007; Mayta et al., 2008) but none of them have been validated under field condi-
tions yet. 
 
There are two available drugs to treat adult T. solium infections: praziquantel and 
niclosamide. Niclosamide is the best choice for adult T. solium infections since it is not 
absorbed from the intestinal lumen. Niclosamide is used as a single dose of 2 gram giv-
en orally. On the other hand, there is a small risk with praziquantel that asymptomatic 
viable cysts in the brain could be affected by the drug and develop neurological symp-
toms like seizures in the patient. The recommended dose of praziquantel is 5 – 10 mg/kg 
given orally on a single dose and under medical supervision (Garcia et al., 2003a).  
 
I.5.2 Cysticercosis 
 
Clinical manifestations of cysticercosis depend on the affected organ or tissue. 
Neurocysticercosis and ophthalmic cysticercosis are often associated with substantial 
morbidity (Garcia and Del Brutto, 2005). Immunodiagnostic methods to detect either cir-
culating antigens or antibodies in serum, cerebrospinal fluid and urine have been de-
scribed (Tsang et al., 1989; Brandt et al., 1992). 
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The enzyme-linked immunotransfer blot (EITB) for circulating antibody detection 
is the WHO recommended screening test for cysticercosis. This assay developed by 
Tsang in 1989, was originally reported to have 98% sensitivity and 100% specificity 
(Tsang et al., 1989) and performs better in field condition than conventional ELISAs 
(Proano-Narvaez et al., 2002). The EITB requires expensive reagents advanced equip-
ment and highly trained technicians to perform the assay. However, when available the 
immunoblot is the best diagnostic tool (Garcia et al., 2003a). 
 
Antigen detection assay has lower sensitivity and specificity than the EITB but 
can detect live parasites. Some assay based in monoclonal antibodies performed well 
on cerebrospinal fluid however there is limited evidence on its sensitivity and specificity 
when the test is performed in serum samples (Garcia et al., 1998; Garcia et al., 2000). 
Since number, localization size and stage of the cysts are important for the physician in 
order to treat the infected patient neuroimaging such us MRI and CT become the most 
important tools for cysticercosis diagnostic in humans. 
 
Until 1978, the only treatment for neurocysticercosis was surgery. Years later, 
Praziquantel became the first specific drug to be used in cysticercosis treatment (Sotelo 
et al., 1984; Sotelo, 1997). Later, albendazole became available and represented a more 
effective, cheaper and convenient way to treat patients (Escobedo et al., 1987; Sotelo et 
al., 1988a; Sotelo et al., 1988b; Escobedo et al., 1989). Cysticercosis outside the central 
nervous system is considered a disorder that does not need to be treated. Porcine cysti-
cercosis is treated using a single dose of 30 mg/Kg oxfendazole given orally (Gonzales 
et al., 1996). 
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I.6 Epidemiology 
 
T. solium/Cysticercosis is a highly endemic parasitic disease in developing coun-
tries where transmission is associated with pigs raised in close contact with humans, 
and with poor hygiene and sanitary conditions (Chatel et al., 1999; Flisser et al., 2006). 
Epidemiological studies carried out during the last two decades have demonstrated that 
cysticercosis is highly prevalent in Cameroon, Tanzania, Zambia, Madagascar, India, 
Nepal, parts of China, Vietnam, Papua New Guinea (Irian Jaya), Mexico, Ecuador and 
Peru among others (Phiri et al., 2003; Rajshekhar et al., 2003; Shey-Njila et al., 2003; 
Wandra et al., 2003; Flisser et al., 2006; Wandra et al., 2006). Although cysticercosis is 
considered an imported disease in developed countries, immigrant domestic workers 
and international travel have increased the prevalence of the disease in these non-
endemic areas (Figure I.6). For example, in the United States cysticercosis has emerged 
as a common cause of seizures among immigrants from Mexico and other endemic 
areas (Schantz et al., 1994; Schantz, 2006). In the US it is estimated that over 1000 
people per year are diagnosed with cysticercosis, the majority of those immigrants from 
endemic countries. Retrospective studies performed by the Health Services in the State 
of California, USA indicated cysticercosis as the cause of death of 124 persons between 
1989 and 2000. In addition, a study carried out at UCLA Medical Center revealed an in-
crease of 14% in NCC admission during the period from 1994 to 1998. Another retros-
pective study showed that 10% of the neurology and neurosurgery admission in Los An-
geles County USC Medical Center were due to NCC during 1994 to 1999. Although the 
majority of cases of NCC as well as tapeworm carriers in the US have been diagnosed 
among immigrants from endemic areas; immigrants become potential foci for disease 
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transmission to other family members and non-immigrant contacts (Sorvillo et al., 2004; 
DeGiorgio et al., 2005a; DeGiorgio et al., 2005b). 
 
NCC affects older children and adults, therefore, serious economic impact due to 
disability are expected (Garcia and Del Brutto, 2005). Studies performed in Mexico and 
published in 1989, (Flisser et al.) estimated a cost of US $15 million per year only in 
hospital admissions of new cases of NCC (Flisser, 1988). In addition, porcine cysticer-
cosis causes the loss of US $43 million per year as a consequence of the confiscation 
and destruction of contaminated carcasses. In Eastern Cape Province (South Africa) the 
cost of T. solium cysticercosis has been estimated to vary from US $18.6 to US $34.2 
million per year with US $5 million corresponding to the cost for the agricultural sector 
(Carabin et al., 2006). For Latin America, porcine cysticercosis accounts for an esti-
mated economic loss of US $64 million (Schantz, 2006). 
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I.7 Control 
 
In an effort to interrupt the transmission, several control measures such as mass 
treatment of pigs, identification and treatment of tapeworm carriers, education and sani-
tation have been implemented and tested (Gonzalez et al., 2003; Sarti and Rajshekhar, 
2003). Mass treatment with praziquantel and niclosamide to eliminate tapeworms from 
human carriers have shown reduction in prevalence of the disease (Allan et al., 1997; 
Sarti et al., 2000). It has also been shown that improvement of pig husbandry, and sani-
tation to deter access by pigs to human feces reduced the prevalence of cysticercosis in 
rural areas (Sarti et al., 1994). 
 
Although a number of intervention trials based on health education and improved 
sanitation have demonstrated that transmission of T. solium can be inhibited temporarily 
(Flisser et al., 2003), it has become clear that an effective elimination of T. solium will 
require sustained pressure on the parasite during both stages of its development 
(Schantz, 2006). Currently, no control intervention has achieved definitive interruption of 
the parasite life cycle, and recrudescence occurs as a consequence of tapeworm rein-
troduction (Schantz et al., 1993; Garcia et al., 2003a; Sarti and Rajshekhar, 2003). One 
measure being considered to help prevent disease reintroduction is vaccination of naïve 
pigs (Lightowlers, 1999). Vaccination of the intermediate host will remove the source of 
human infection and therefore the T. solium life cycle would be interrupted (Flisser et al., 
1979; Lightowlers, 1999; Lightowlers, 2003).  
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I.7.1 Vaccination 
 
Immune response generated by Taenia infection is basically antibody mediated. 
During the sixties, Gemmel and Blundell reported that the immune response against 
Taenia infection is composed of an early and a late immune response (Blundell et al., 
1968; Gemmell et al., 1968; Blundell et al., 1969). The early immune response may act 
at the intestinal level, while the late immune response does it at the site of metacestode 
development. In addition, he also described that antibodies generated during the early 
stage of infection are likely to be protective and that these antibodies were likely to be 
generated against metabolic products of embryos undergoing metamorphosis (Gemmell 
and Lawson, 1989; Lightowlers, 1990). Based on these observations, studies were con-
ducted in order to identify each oncosphere antigen. In the particular case of T. ovis, 
studies identified several antigenically distinct oncosphere antigens. Three of these anti-
gens, To45W, To16 and To18 were cloned, expressed in E. coli, and shown to be pro-
tective against challenge (Harrison et al., 1993; Harrison et al., 1996). T. ovis oncos-
phere work lead to the identification and cloning of homologs of these three antigens: 
from T. saginata and T. solium as well as from Echinococcus granulosus (Johnson et al., 
1989). Some of these antigens have been tested and found to be protective for the in-
termediate host (Lightowlers et al., 2003; Flisser et al., 2004; Gonzalez et al., 2005). 
 
For T. solium, homologs to To45W and To18 known as Tsol45 and Tsol18 have 
been cloned and tested in 5 different trials (Table I.1 and Table I.2). The first vaccination 
trial performed in Mexico showed 100% protection in those animals immunized with 2 
doses of 200 µg of recombinant GST-Tsol18 fusion protein; whereas, vaccination with 
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Tsol45 showed no protection. On a second trial also performed in Mexico, 4 doses of 
recombinant Tsol45 were necessary to obtain protection levels similar to those obtained 
with Tsol18 (Flisser et al., 2004).  The third trial performed in Cameroon, tested only 
Tsol18 and showed 100% of protection. The fourth and fifth trials were performed in Pe-
ru. Both of them showed high levels of protection in animals immunized with Tsol18 
(Gonzalez et al., 2005). 
Table I.1 Induction of protection against Taenia solium cysticercosis in pigs afforded by 
vaccination 
 
Vaccine 
 
Location 
 
Dose 
 
No. Animals 
 
Mean No. of 
cysts per ani-
mal 
 
Protection 
(%)* 
 
GST (control) 
 
Peru 
 
2 doses 
 
5 
 
1599.2 
 
0 
GST/MBP Peru 2 doses 5 1669.4 0 
GST/Tsol 18 Peru 2 doses 8 0.5 99.9** 
GST/MBP/ Tsol45 Peru 2 doses 8 22.3 98.6** 
GST (control) Mexico 2 doses 5 256.8 0 
GST/Tsol18 Mexico 2 doses 5 0 100 
GST/Tsol45 Mexico 2 doses 5 136.2 46.96 
GST/Tsol18-GST/Tsol45 Mexico 2 doses 5 13.6 94.7** 
GST (control) Mexico 4 doses 12 41.8 0 
GST/Tsol18 Mexico 3 doses 5 0.2 99.5** 
GST/Tsol45 Mexico 4 doses 5 1.2 97.1** 
None Cameroon 2 doses 5 30 0 
GST/Tsol18 Cameroon 2 doses 5 0 100*** 
* Protection was calculated as the percent reduction in the mean number of cysticerci in each group in comparison with 
the mean in the respective control 
Data from (Flisser et al., 2004; Gonzalez et al., 2005). 
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Tsol18 is a homolog to the 18 kDa protective oncosphere antigen from T. ovis 
(To18).  Tsol18 gene has 3 exons and 2 introns.  Two small exons encode for the amino 
and the carboxy terminal domain. A single larger exon encodes the protein. In addition, 
Tsol18 also has an intron in the 3’untranslated region (UTR) (Gauci et al., 1998; Gauci 
and Lightowlers, 2003).  Analysis of the predicted protein sequence encoded by the first 
exon shows the presence of a hydrophobic domain at the N-terminus which is likely to 
be a secretory signal. The second exon encodes for a fibronectin type III domain (FnIII) 
which is conserved among all the protective Taenia oncosphere antigens characterize 
thus far (Gauci and Lightowlers, 2003; Gauci et al., 2006). FnIII domains are highly con-
served and have 100 aminoacids arranged into a β sandwich fold composed by three β 
strands in one sheet and four in the other one. Tsol18 has a single copy of this domain. 
Tsol18 mature protein (Genebank accession N° AF017788) codes for 113 amino acids 
which includes a group of 14 aminoacids (from Threonine at position 3 to phenylalanine 
at position 26) at the beginning of the sequence forming a hydrophobic area (Figure I.7). 
Tsol18 has a molecular weight of 12.8 kDa; a putative glycosylation site, and is specifi-
cally expressed during the oncosphere stage (Gauci et al., 2006). 
 
Figure I.7 Mature Tsol18 Hydrophobicity plot (Kyte-Doolittle scale) 
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I.8 Purpose of the Study 
 
Genetic manipulation of Salmonella species has resulted in the loss of their pa-
thogenicity without interfering with their ability to stimulate the immune system. In this 
regard, attenuated Salmonella has the ability to generate a strong mucosal immune re-
sponse in addition to the humoral and cellular immune responses not only against self 
antigens, but also against recombinant ones (Dougan et al., 1989). Attenuated and im-
munogenic strains of Salmonella can be genetically engineered to stably express foreign 
antigens. Recombinant strains used as vaccine delivery systems, usually have a plasmid 
vector that harbors the sequence for the foreign antigen (Chatfield et al., 1993; Chatfield 
et al., 1994). These plasmids have to be stably maintained in the bacteria in order to in-
duce an immune response against the recombinant antigen. Stable expression of foreign 
antigens can be accomplished by integration of the genes specifying for the foreign anti-
gen into the bacteria chromosome.  Another approach for stable and high level expres-
sion is the balanced-lethal host-vector (Curtiss III, 1989; Curtiss et al., 1989b; Curtiss et 
al., 1990; Curtiss et al., 1994). The stable balanced-lethal host-vector uses an atte-
nuated strain of Salmonella harboring a mutation in the β-aspartate semi-aldehyde de-
hydrogenase (asd) which imposes a requirement for diaminopimelic acid (DAP), and a 
plasmid vector that complemented that defect in which the recombinant protein is 
cloned. Thus, loss of the plasmid resulted in cell death and lysis. Several foreign anti-
gens from pathogens closely related to Salmonella and also from viruses, or parasites 
have been expressed in recombinant avirulent Salmonella and tested for safety and effi-
cacy against challenge in animal models (Koji Nakayama, 1988). Good immune res-
ponses were observed when the foreign antigen is retained in the cytoplasm of the re-
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combinant Salmonella as well as when foreign antigens are localized to the periplasmic 
space, or to the outer membrane (Khan et al., 1994; Chabalgoity et al., 1997; Villarreal-
Ramos et al., 1998; Kang et al., 2002).   
 
Recently, Lightowlers and others have shown that the oncosphere antigen known 
as Tsol18 can confer protection when it is administrated as a recombinant GST fusion 
protein in 2 doses of 200 µg each or as a His-tagged protein (Flisser et al., 2004; Gonza-
lez et al., 2005; Hancock, unpublished data). Although Tsol18 has been proved to be a 
good vaccine candidate, the production of a recombinant protein for vaccine use is ex-
pensive, and therefore impractical for large-scale use. The use of recombinant atte-
nuated Salmonella strains to deliver the vaccine candidate will not only reduce the cost 
of vaccine production but also will reduce the numbers of vaccine doses needed per an-
imal, since one dose will be enough to protect pigs from infection during its productive 
life. Reduction in the number of doses per animal will also facilitate animal management 
in field. Consequently, the aim of this proposal was to develop and test the efficacy of a 
safe, effective and inexpensive delivery system for the T. solium cysticercosis vaccine 
candidate Tsol18 that can be added to the already existing control measures and be 
used in eradication programs in field trials. For this purpose, an attenuated strain of 
Salmonella enterica var typhimurium was used as a vector to deliver the vaccine candi-
date. The attenuated Salmonella (∆asd) strains and the plasmids that complement this 
mutation were available for research in collaboration with Dr. Roy Curtiss III Co-director 
of the Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State 
University. The vaccine efficacy was tested by vaccination and challenge of naïve pigs.  
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Immunity to infection with the larval stage of cestodes parasites is antibody me-
diated. Early experiments performed in Taenia ovis demonstrated that protection can be 
afforded by the passive transfer of antibody. In order to study and follow the specific im-
mune response generated by the Salmonella vaccine construction a serological test in a 
FAST-ELISA format was developed. The FAST-ELISA was used to quantify and follow 
the specific immune response in vaccinated animals to establish a correlation between 
the antibody levels and protection against challenge. 
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II. Development and optimization of the FAST-ELISA to detect protective antibo-
dies against cysticercosis in vaccinated pigs 
 
II.1 Introduction 
 
Cysticercosis is a parasitic infection produced by the larval stage of Taenia so-
lium (Flisser, 1994). The life cycle of this parasite requires 2 hosts: an intermediate host, 
the pig, where the cysts develop; and a definitive host, humans, for the adult tapeworm 
(Flisser, 1986; Garcia and Del Brutto, 2000; Garcia and Del Brutto, 2005). Although pigs 
act normally as intermediate hosts, humans accidentally infected with Taenia solium 
eggs can also develop cysts. In humans, the most commonly observed location of the 
larvae is the central nervous system (CNS) where they cause a disease known as neu-
rocysticercosis (Garcia and Gilman, 1995; Garcia et al., 1999). Neurocysticercosis often 
causes seizures and it is responsible for substantial mortality and morbidity in develop-
ing countries (Lightowlers and Gauci, 2001). 
 
Control and eradication programs have shown that transmission of the disease 
can be interrupted temporarily but recrudescence occurs as a consequence of tapeworm 
reintroduction and infection of naïve pigs (Garcia et al., 2006). Controlling porcine cysti-
cercosis is vital for eradication and control programs (Garcia et al., 2003b; Gonzalez et 
al., 2003; Flisser et al., 2006). Studies on immunizing pigs with recombinant vaccine an-
tigens derived from oncospheres showed that one of the vaccine molecules was capable 
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of inducing protection in 99% of the vaccinated animals against challenge when it is ad-
ministrated in 2 doses of 200 µg each (Flisser et al., 2004; Gonzalez et al., 2005). Stu-
dies on the immune response generated by the recombinant vaccine using a conven-
tional ELISA have been previously reported (Kyngdon et al., 2006a). However, conven-
tional ELISAs cannot be considered truly quantitative assays since they require a dilution 
titration of the sera and an end point determination (Tsang et al., 1980; Tsang et al., 
1983b). 
 
A quantitative, simple and rapid serologic assay based on the Falcon assay 
screening test (FAST-ELISA) has been previously developed and used to follow the 
progress of infection and treatment in many diseases (Tsang and Chau, 1987; Levine 
and Brumley, 1989; Fagbemi and Hillyer, 1990; Hillyer and Soler de Galanes, 1991; 
Tsang and Wilkins, 1991; Hillyer et al., 1992; Azab et al., 1999). Therefore; the objective 
of this study was to develop a quantitative FAST-ELISA to detect protection-associated 
antibodies in pigs vaccinated against cysticercosis.  
 
To develop this quantitative assay we have cloned, sequence, produce and puri-
fy the cysticercosis protective antigen rTsol18. This paper describes the FAST-ELISA for 
detection of specific antibodies against Taenia solium-cysticercosis protective antigen 
rTsol18. In addition, we used the developed test to follow the specific immune response 
in vaccinated pigs. This test not only meets the criteria of easy operation and quantifica-
tion but will allow us to monitor vaccinated animals.    
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II.2 Materials and Methods 
II.2.1 FAST – ELISA 
 
The FAST ELISA system consists of sticks molded on to a lid that fits a 96-wells 
ELISA plate. The antigen is adsorbed on to the sticks, washed and exposed to serum 
antibodies, enzyme-conjµgated anti-porcine 2nd antibodies, and substrate in 5 minutes 
incubations. The reaction is stopped by removing the sticks from the substrate. All the 
steps for the FAST ELISA were performed as previously described (Hancock and Tsang, 
1986; Handali et al., 2004). 
 
Briefly, sticks (transferable solid phase screening, catalog #445497; Nunc, 
Roskilde, Denmark) were sensitized with the antigen diluted in 0.05M Tris/HCl, 0.3M 
KCl, 2.0 mM ethylenediaminetetracetic acid (EDTA); pH 8.0(sensitization buffer)  in 96-
well plates (Nunc, catalog #2696200) for 2 hours in an orbital shaker (Titer Plate Shaker; 
Laboratory-Line Instruments, Melrose Park, IL) at room temperature (RT). Previous stu-
dies have shown that absorption of antigens to polystyrene occurs within 2 hours of in-
cubation at RT (Tsang et al., 1980). 
 
After sensitization sticks were washed with 0.15M NaCl in 0.01M 
Na2HPO4/NaH2PO4; pH 7.2 (PBS), containing 0.3% tween 20 (Sigma Chemical Compa-
ny) using a garden sprayer. Washes were performed after each incubation step. After 
each wash, the sticks were rinsed with deionized water. Pig sera were diluted 1:200 in 
PBS; 0.3% tween 20; 5% nonfat dry milk and tested in triplicates. Samples with activity 
higher than the maximum point in the standard curve were further diluted and retested 
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until their activity fell within the standard curve. In homemade affinity purified goat anti 
porcine IgG (heavy and light chain), horseradish peroxidase labeled and diluted, 1:3000 
was used as conjugate (Tsang et al., 1995).  3, 3’, 5, 5’Tetramethylbenzidine; TMB-Sure 
blue (Kirkegaard and Perry Laboratories) was used as substrate. The substrate solution 
was dispensed into the plate and the sticks were incubated again as in the previous 
steps for 5 minutes. The reaction was stopped by removing the sticks from the substrate.  
The absorbance was measured at 630 nm in a ThermoMax microtitration plate reader 
(Molecular Devices, Sunnyvale, CA). The concentration of each sample was derived 
from the standard curve and expressed in micrograms/ml. 
 
II.2.2 Standard curve preparation 
 
The immunoglobulin G (IgG) standard curve was prepared as described by 
Scheel (Scheel et al., 2006). Briefly, normal porcine immunoglobulin G (PrIgG) was pre-
cipitated using ammonium sulfate (NH4)2SO4; purified by ion exchange chromatography 
using a Gamma G Hi-Trap (Amersham Biosciences) column and quantified by Bradford 
protein assay. Purified PrIgGs were stored in liquid nitrogen until use. In order to prepare 
the standard curve, PrIgGs were diluted in PBS; pH 7.2, 0.1% sodium azide, 0.001% 
bovine serum albumin (BSA) fraction V, protease free (Catalog No:3116999001, 
ROCHE) to a working dilution of 100 µg/ml. A pilot curve of 11 points was constructed in 
the following concentrations (µg/ml): 12.5, 6.25, 3.18, 1.6, 0.8, 0.4, 0.2, 0.1, 0.05, 0.025 
and 0. The diluted standards were stored at -4° C. The standards were assigned with 
reactivity values that corresponded with their concentration. The standard curve was 
tested in triplicates. 
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II.2.3 Optimization of assay reagents 
 
In the FAST-ELISA format all the reagents with the exception of the one being 
measured need to be added in excess. To determine the amount of antigen to be consi-
dered in excess the antigen titration was performed. Briefly, decreasing 2-fold dilutions 
of Tsol18 in sensitization buffer (from 10µg/ml to 0µg/ml) were coated onto the beads in 
triplicates. In order to titrate the antigen, the remaining reagents used for the ELISA were 
added in excess. Sera from a hiperimmunized goat diluted 1:4 was used as a source of 
antibodies. Titration of the conjugate was performed by assaying several conjugate dilu-
tions. Antigen and antibody in excess were used for the assay. A conjugate dilution of 
1:3000 in PBS- 0.3% tween 20 was determined to be in excess.  
 
II.2.4 Antibody titration 
 
An antibody titration was performed using a pool of serum from vaccinated pigs 
to determine the dynamic range of the assay. For the titration, plates were sensitized 
with 2µg/ml of purified Tsol18 antigen (this is antigen in excess). Serial 2-fold dilutions of 
the positive pool sera in PBS - 0.3% tween 20/ 5% non fat milk were assayed in tripli-
cates in FAST-ELISA. A serial 2-fold dilution of normal porcine sera was assayed in the 
same plate as a control. Signal to noise ratio was calculated for each sera dilution. 
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II.2.5 Sera samples 
 
In this study we used porcine samples from a previous unpublished vaccine trial. 
The immunization doses and necropsy results are shown in table 1. Briefly, 8 two-month 
old piglets were immunized twice with GST/Tsol18 200 µg in 1 mg of Quil A. A Control 
group with seven animals immunized with the GST leader sequence only in 1mg of Quil 
A was included in the study. Vaccination was performed intramuscularly on day 0 and 
day 15. Animals were kept in an animal facility at San Marcos University in Lima. Fifteen 
days after second vaccination (day 30) animals were orally challenged with one proglot-
tid of Taenia solium obtained from treated patients. Pigs were slaughtered three months 
after challenge and the carcasses were dissected in order to determine the parasite bur-
den. Cysts founded in each animal were categorized as viable (capable of evagination) 
or degenerated.  Serum samples were collected every 15 days. All samples were tested 
in triplicate. Sera samples were run in triplicate at 1:80 sera dilution. Samples with anti-
body activities higher than that of the standard curve were further diluted and re-
assayed. Specific anti Tsol18 IgG concentration was calculated based on the activity of 
the standard curve. Correlation between the antibody response and the number of cysts 
was calculated using Spearman’s test. 
 
II.2.6 Assay variability 
 
Inter and intra assay variation were determined as previously described (Han-
cock and Tsang, 1986). Briefly, to determine the intra assay variation we used the coef-
ficient of variation (CV) of five samples run in separate plates. The inter assay variability 
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was calculated using a positive reference sample that was run 20 times over a 3-week 
period. 
 
II.3 Results 
II.3.1 Antigen excess 
 
Determination of reagents in excess was done by titration. Fast ELISA Tsol18 
antigen titration showed that the saturation of the polysterene beads by antigen occurred 
at 1 µg/ml ( 
Figure II.1). Therefore, antigen in excess was found to be higher or equal to 
1µg/ml.  
 
 
 
Figure II.1 Recombinant Tsol18 antigen titration. 
 
 
34 
 
II.3.2 Standard curve 
 
Normal porcine IgG standard curve was constructed as described above and its 
activity was measured in the FAST-ELISA format. The test was repeated in three differ-
ent plates under the same conditions. An 11 point normal IgG standard curve was sensi-
tized to the sticks for 2 hours and then exposed to the conjugate and substrate as de-
scribed above. We selected a 9 points standard curve (0; 0.05; 0.1; 0.2; 0.8; 1.6; 6.25; 
12.5 µg/ml) to be included from now on in each test (data not shown). The standard 
curve selected had sigmoideal shape that fitted a 4 parameter logistic model with an r 2 = 
0.989. This curve was included in all subsequent assays. 
 
II.3.3 Sera titration 
 
Sera titration was performed using antigen and conjugate in excess to establish a 
optimal assay concentration in order to fit within the dynamic range of the FAST-ELISA. 
The optimal assay concentration to be used for most sera to be tested by the FAST-
ELISA was 1:80 in PBS - 0.3% tween/5% milk. Noise to signal ratio at the chosen dilu-
tion was 35 (Figure II.2). 
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Figure II.2 Porcine sera titration. 
 
Titration of positive and normal porcine pool sera was performed with antigen, 
conjugate and substrate in excess in the FAST-ELISA format. 2-fold dilutions of each 
sera starting at 1:5 were exposed to the rTsol18 antigen. The arrow shows the 1:80 sera 
dilution. Titration of the positive porcine sera is showed in filled circles, the negative in 
open circles. 
 
II.3.4 Serum 
 
A total of 90 serum samples from 15 piglets from a vaccination trial were as-
sayed. Results from the vaccine trial are shown in table 1. Specific serum IgG concen-
tration was determined by FAST-ELISA in pigs following immunization with GST-Tsol18 
in Quil A. In all pigs vaccinated with GST-Tsol18 (n=8) the antibody response against 
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rTsol18 showed a similar pattern.  Antibodies were detected as early as 15 days after 
the first immunization and raised to their highest concentration at a mean +/- SE of 5.6 
+/- 0.8 µg/ml by day 30 (Figure II.3). 
 
After day 30 the antibody concentration started to decrease. At the end of the 
study, antibody levels for the vaccinated animals were at a mean +/- SE of 1.6 +/- 0.22 
µg/ml. Animals with no viable cyst at necropsy showed an antibody concentration at a 
mean +/- SE of 5.9 +/- 0.92 µg/ml at the time of challenge on day 30 (Figure II.3). Only 
one vaccinated animal had viable cysts at the time of necropsy (Table II.1). The amount 
of antibodies in this animal at the time of challenge was 3.2 µg/ml.  The control group 
(n=7) showed an antibody response of 0.3 +/- 0.1 µg/ml at the time of challenge (Figure 
II.3).There was no change in the immune response through the experiment in this group.  
All animals but one in the control group had viable cysts at necropsy, however; in this 
animal degenerated cysts (651) were found. This animal showed an antibody concentra-
tion of 0.9 µg/ml at the time of challenge. The correlation between the antibody res-
ponses at the time of challenge and the number of viable and total number of cysts (via-
ble and degenerated) were -0.82 and -0.84 respectively. 
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Figure II.3 Specific antibody response in vaccinated and control pigs 
 
Serum samples from 2 months old piglets immunized with GST-Tsol18 were as-
sayed for specific antibody response. Animals were immunized on days 0 and 15 and 
challenged on day 30. Serum was collected every 15 days. The mean of the antibody 
concentration +/- SE for each specific day for both vaccinated (n=8) and control (n=7) 
groups is shown. 
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II.3.5 Assay variability 
 
The intra- and- inter assay variability for the FAST-ELISA was determined. The 
inter- and intra-assay CV were 5.8% and 4.2% respectively. The concentration reading 
of the positive reference sample in each run must fall within this established CV value to 
be valid. 
 
II.4 Discussion 
 
The usefulness of the conventional enzyme-linked immunosorbent assay (ELI-
SA) as a diagnostic and research tool for either antigen or antibody detection is evident 
and has been previously revised (Scharpe et al., 1976). However, it has some draw-
backs: 1) Long incubation periods: some incubation should be performed for as long as 
3 hours. 2) Requires multiple sample dilution titrations which make the assay labor in-
tensive. 3) The substrate incubation exceeds the point where the enzyme concentration 
is linear with respect of activity and therefore, results can be only considered semi quan-
titative (Dixon, 1974). 4) Results depend on and endpoint determination in the presence 
of a stop solution that may not be efficient. 5) Results are reported as the highest dilution 
generates a color intensity and not as concentration (Tsang et al., 1983a). 
 
The FAST-ELISA is a quantitative assay. Like any other ligand-binding quantita-
tion assay it requires that all the reagents, with the exception of the one being assayed 
to be used in excess, and that the enzyme activity must be measured when the amount 
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of substrate present is much greater than that of the enzyme in the reaction (Avrameas, 
1976; Avrameas, 1983; Hancock and Tsang, 1986). In the FAST-ELISA a standard 
curve is used to determine the levels of reactivity of the unknown samples and ex-
pressed in concentration units. The use of the standard curve also allows us to use a 
single dilution of the sera and to compare results from laboratory to laboratory when they 
are using an equivalent standard curve (Hancock and Tsang, 1986). 
 
The assay we have developed and reported here has several advantages: (1) A 
single dilution of the sample is assayed. (2) The reactivity of the unknown samples is 
quantified. (3) Low inter- and intra-assay variation. (4) Using the same standard curve, 
results are comparable. (5) Only 5 minute incubations. (6) Reasonable cost per test. 
About US $0.18 per sample run in triplicate (7) Easy to perform and its configuration 
makes it suitable to be adapted for use in field work.  
 
Taenia solium cysticercosis is a potentially eradicable disease (Aarata A.A, 
1992). Control and eradication measures such as identification and treatment of tape-
worm carriers, treatment of pigs, education and sanitation have been implemented in 
field. Despite all these efforts, disease transmission can only be interrupted temporarily 
and recrudescence occurs as a consequence of tapeworm reintroduction and infection 
of naïve pigs (Gonzalez et al., 2003). Vaccination of pigs is a measure being tested by 
us as an adjunct in control programs. 
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Our optimized FAST-ELISA was able to detect specific anti Tsol18 protective an-
tibodies in vaccinated animals and to follow the immune response up to 80 days after 
vaccination.  The higher concentration of specific IgGs was found on day 30 which was 
the day of challenge. Additionally, we have found a strong correlation between the anti-
body concentration and the number of viable and total cysts (-0.82 and -0.84 respective-
ly). The FAST-ELISA as described herein will serve as a useful tool to follow the immune 
response in vaccinated animals in the field to determine if they are indeed protected.  
 
In conclusion, we have developed a quantitative; simple and rapid assay for de-
tection of specific antibodies against rTsol18. The FAST-ELISA for detection of specific 
antibodies against rTsol18 can measure the immune response in vaccinated pigs. More-
over, this antibody response strongly correlated not only with the number of both viable 
and recovered degenerated cysts. The assay we presented here could be helpful for 
monitoring the immune response of vaccinated animals in field. 
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III. A recombinant attenuated Salmonella vaccine system for Taenia solium cysti-
cercosis infection in pigs 
 
III.1 Introduction 
 
Orally administrated, attenuated strains of Salmonella enterica serovar Typhimu-
rium are capable of colonizing gut associated lymphoid tissue and inducing an immune 
response (Galan, 1996b; Galan, 1996a) . These avirulent Salmonella strains have been 
constructed by introducing mutations in genes required for virulence and modified to ex-
press another pathogen antigen in order to be used as an oral delivery vaccine system 
(Curtiss and Kelly, 1987; Curtiss et al., 1994). Stable and high level expression of hete-
rologous antigens can be achieved using a multicopy plasmid that is stably maintained in 
the host (Curtiss et al., 1989a; Curtiss et al., 1989b; Curtiss et al., 1990). To enable for-
eign antigen expression and delivery by the vaccine strain, a balanced-lethal host-vector 
system has been developed. In this system, the salmonella strain possesses a deletion 
mutation in the β-aspartate semi-aldehyde dehydrogenase (asd) gene coding for diami-
nopimelic acid (DAP), an essential constituent of the bacterial cell wall and the plasmid 
vector possesses the wild-type asd allele that complements the chromosomal deletion. 
Loss of the plasmid results in cell death and lysis (Koji Nakayama, 1988). 
. 
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Cysticercosis is a parasitic infection produced by the larval stage of Taenia so-
lium, which affects pigs and humans following ingestion of the eggs of this cestode 
(Flisser, 1994; Garcia and Del Brutto, 2000; Sciutto et al., 2000). In humans, the clinical 
importance of the disease appears when the larvae develop in the central nervous sys-
tem producing a neurological disorder known as neurocysticercosis (NCC) (Garcia et al., 
1999; Garcia et al., 2002a; Garcia et al., 2002b; Garcia et al., 2003a). Although there is 
an active infection, the disease remains silent until the cysts start to degenerate and in-
duce an immune mediated inflammation which results in clinical manifestation of the dis-
ease (Garcia et al., 2002a). 
 
Transmission of the parasite can be interrupted by improving public sanitation, 
mass treatment of pigs, identification and treatment of tapeworm carriers (Sarti et al., 
1992; Sarti et al., 1997; Sarti et al., 2000; Gonzalez et al., 2003; Sarti and Rajshekhar, 
2003). However; no control intervention has achieved definitive and sustainable interrup-
tion of the Taenia solium life cycle. The presence of a susceptible intermediate host 
permitted reintroduction of the parasite.  Vaccination of pigs in combination with the in-
terventions mentioned above may provide the opportunity to definitively interrupting T. 
solium transmission (Lightowlers, 1999). The potential for effective vaccination of pigs 
has been demonstrated. Recently, Lightowlers and others have shown that the oncos-
phere antigen known as Tsol18 can confer protection when it is administrated as a re-
combinant GST fusion protein in 2 doses of 200 µg each (Flisser et al., 2004; Gonzalez 
et al., 2005). Although Tsol18 has proved to be a good vaccine candidate, the produc-
tion of a recombinant protein for vaccine use is expensive, and therefore impractical for 
large-scale use. Therefore, it becomes essential to develop a safe, easy to use and cost 
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effective vaccine capable to induce long-lasting immune response.  In this regard, the 
use of attenuated Salmonella strains to deliver heterologous antigens represents an at-
tractive alternative for vaccine development.  
 
The objective of the present study was to develop a safe, effective, inexpensive 
and practical delivery system for the protective antigen Tsol18 using an attenuated strain 
of Salmonella enterica serovar Typhimurium as a vector and to test its immunogenicity 
and efficacy in mice and pigs respectively. For expression of the recombinant protein we 
used a balanced-lethal host-vector system. In this report we describe a recombinant at-
tenuated Salmonella vaccine (RASV) system that is able to express Tsol18, induce a 
specific humoral immune response against Tsol18 antigen and Salmonella antigens in 
immunized mice and pigs and is capable of reducing the infection burden in vaccinated 
pigs. 
 
III.2 Materials and methods 
III.2.1 Bacterial strains, plasmids, culture media and growth conditions 
 
The bacterial strains and plasmids used for the construction of the recombinant 
attenuated Salmonella vaccine (RASV) against Taenia solium cysticercosis are listed in 
Table III.1 and were kindly provided by Roy Curtiss III, Co-director of The Biodesign In-
stitute at Arizona State University. Escherichia coli and Salmonella enterica serovar Ty-
phimurium cultures were grown with aeration, at 37 C in Lennox broth or agar (Difco, 
Detroit MI) supplemented with 0.5% glucose; 0.2% mannose and 0.2% arabinose. When 
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required; tetracycline was added to a final concentration of 50 µg/ml. Diaminopimelic ac-
id (DAP) was added to obtain a final concentration of 50 µg/ml for growth of the asd - 
strains. Arabinose was depleted from the media to induce expression of the recombinant 
protein. 
 
Table III.1 Bacterial and plasmid strains used in this study 
 
 
Bacterial strains 
or Plasmid 
 
Genotype or characteristic 
 
Source 
 
Plasmid 
 
pYA3620 
 
 
 
 
3160 bp; asd+; β-lactamase secre-
tion vector. 
 
 
 
Curtiss Lab 
Strains 
E. coli 
  
 
 
χ 6212/pYA232 F – λ – Φ80 ∆(lacZYA-argF) end A1 
recA1 hsdR17 gyrA96 relA1 
∆asdA4, Tetracycline resistant. 
Curtiss Lab 
 
 
S. enterica 
Var.Typhimurium  
χ9402 
 
 
∆asdA21, ∆pmi-2426,∆(gmd-fcl)-26 
∆Pfur81,∆Pcrp527, ∆araBAD23, 
∆araE25, ∆relA198, ∆sopB1925 
 
 
Curtiss Lab 
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III.2.2 DNA procedures 
 
DNA manipulations were conducted using standard molecular biology proce-
dures (Sambrook, 1989). PCR amplification was used to obtain DNA fragments for clon-
ing. PCR conditions were as follow: denaturation at 95°C for 30 seconds, primer anneal-
ing at 60°C for 30 seconds, polymerization at 72°C for 30 seconds (30 cycles) and a final 
extension at 72°C for 7 minutes. PCR products were visualized in a 1% agarose gel. 
Transformation of E. coli and Salmonella was performed by electroporation (BIO-RAD, 
California). Transformants containing the asd+ plasmid were selected in lennox; 0.2% 
mannose; 0.5% glucose; 0.2% arabinose agar plates without DAP. Only clones contain-
ing the recombinant plasmid were able to grow under these conditions.  
 
III.2.3 Recombinant plasmid construction 
 
E. coli 6097/pYA232 was used as intermediate host strains for the cloning. For 
antigen delivery to the bacterial periplasmic region plasmid pYA3620 containing the β 
lactamase secretion system was used. Mature Tsol18 sequence was amplified (forward 
EcoRI: 5’ -GGA ATT CGA CCG AAC ATT CGG CGA CGA TAT TTT CGT G- 3’; reverse 
PstI: 5’ –AAC TGC AGC GAT CTT CGG ACC TTC TTG TGC TTG ATC TGC- 3’) and 
cloned into pYA3620 to yield plasmid pYA3620/Tsol18. In frame cloning was confirmed 
by nucleotide sequencing. After cloning the recombinant plasmid was transformed into 
the intermediate host; purified and transformed into Salmonella. Success of transforma-
tion was confirmed by PCR and nucleotide sequencing using a specific set of primers 
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that amplified the recombinant plasmid (Forward: 5’- AAA GAG ATG TGC GGA TCT 
TCC- 3’; Reverse: 5’ TCA GGC TGA AAA TCT TCT CTC ATC- 3’). 
 
III.2.4 Expression test 
 
To test the expression of recombinant Tsol18 by Salmonella enterica var typhi-
murium and E. coli, transformed bacteria were grown over night at 37C with shaking at 
300 rpm. The overnight culture was diluted 1:50 and grown in the absence of arabinose 
for 4 hours. Cultures were harvested by centrifugation at 5000 x g, 4C, 5 minutes. The 
pellet from 50 ml culture was suspended in 50mM Tris/HCl, pH 8.0, 8M urea, 2% SDS, 
0.1% bromophenol blue; and boiled for 5 minutes. Proteins were separated by electro-
phoresis in a 5% to 22.5% gradient sodium dodecyl sulfate polyacrylamide gel (SDS-
PAGE), transferred to a nitrocellulose membrane then washed and exposed to goat anti 
Tsol18-POD labeled  (1:200) (Tsang et al., 1995). Bound antibodies were visualized with 
DAB (3,3’ diaminobenzidine) substrate solution (Tsang et al., 1989). 
 
III.2.5 Plasmid stability 
 
A single colony of the transformant was grown in 3 ml of media supplemented 
with DAP overnight. A 1:1000 dilution into the same type of media was performed the 
following day. Inoculated cultures were grown under standard conditions for 14 hours 
(approximately 10 generations), after which a 1:1000 dilution was performed again. This 
process was repeated for 5 consecutive days. To determine the proportion of cells re-
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taining the asd+ plasmids, dilutions of 10-5 and 10-6 from each culture after 14 hours of 
growth were plated onto Lennox agar plates supplemented with 0.5% glucose; 
0.2%mannose, 0.2% arabinose and DAP. The following morning, 100 colonies were 
picked and patched in the same kind of agar plates that were either unsupplemented or 
supplemented with DAP. Colonies in both plates were counted after 24 hours of incuba-
tion and the percentage of colonies retaining the plasmids was determined. 
 
III.2.6 Phenotype characterization 
 
The presence of the ∆asdA21 mutation in Salmonella χ9402 was confirmed by 
the inability of the strain to grow in media without DAP. Lypopolisaccharides (LPS) pro-
files of Salmonella transformants were examined by SDS-PAGE using previously de-
scribed methods (Hitchcock and Brown, 1983). 
 
III.2.7 RASV preparation 
 
For the vaccine inoculum RASV strains were grown overnight at 37C with aera-
tion. The following day, 100 ml of media were inoculated with 1 ml of the overnight cul-
ture (1:100) and grown with aeration (300 rpm) at 37C to an OD600 of 0.8 to 0.9. Cells 
were centrifuged at room temperature (7000 x g for 15 minutes) and the pellet was re-
suspended in 1 ml of buffered saline with gelatin (BSG).  
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III.2.8 Mice experiment 
 
Twenty female pathogen free mice were immunized with either one or two doses 
of Salmonella χ9402 harboring pYA3620-Tsol18. Mice were orally inoculated with 50 ul 
of BSG containing 109 CFU. Control groups of four mice each were immunized with Sal-
monella χ9402 containing the empty plasmid. Blood samples were collected every 2 
weeks for 10 weeks. 
 
III.2.9 Porcine challenge 
 
To test vaccine immunogenicity and efficacy in piglets; sixteen 2-months old, cys-
ticercosis free piglets were randomly distributed in 2 groups. Piglets were orally immu-
nized with 500 µl of BSG containing 1012 CFU. The control group received the salmonel-
la vaccine vector containing an empty plasmid. Four weeks after immunization, piglets 
were orally infected with one proglottid of T. solium. Animals were observed for 2 hours 
after infection and kept isolated in an experimental animal facility for four months. Serum 
samples were collected weekly for 12 weeks, thereafter every 2 weeks. Piglets were ob-
served twice a day and a clinical exam was performed on a daily bases.  
 
Ninety days after challenge, all pigs were sacrificed using an over dose of anes-
thesia. Animals were carefully examined following the standard necropsy procedure. En-
tire musculature, diaphragm, heart, masseters, tongue and brain were dissected in small 
slices and examined for the presence of cysts. The total number of cysts in each animal 
was counted and recorded. Cysts were classified as viable or degenerated based on its 
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macroscopic appearance. A sample of viable cysts from each animal was tested for in 
vitro evagination in bovine bile (Gonzalez et al., 1997). 
 
III.2.10 Recombinant Tsol18 and Salmonella antigens preparation 
 
Tsol18 mature sequence was cloned into a pET100 vector; expressed in E. coli 
(BL21 Star) (Invitrogen, San Diego, CA) and purified by nickel affinity column chromato-
graphy (His-Trap GE Healthcare). The 6X his leader sequence was cleaved with entero-
kinase (1U/20 µg/30ul) (Invitrogen, San Diego, CA) and removed by affinity purification 
using a soybean trypsin inhibitor column (Pierce, Rockford IL). The unbound peak con-
taining naked Tsol18 (13.4 kDa) was re-purified by Ni affinity chromatography.  
 
Salmonella outer membrane proteins (SOMPs) antigen was prepared as follows. 
An overnight culture of Salmonella χ9402 was diluted 1:100 in Lennox broth and growth 
at 37C with aeration (300 rpm) to an OD 600 of 1. The bacterial culture was then pelleted 
by centrifugation (6000xg for 15 minutes at 4C). The pellet was resuspended in 10mM 
HEPES buffer on ice and sonicated. The lysate was centrifuged at 14000 x g for 30 mi-
nutes. The pellet was resuspended in HEPES buffer; 2% sodium lauryl sarcosinate (sar-
kosyl) (Merck) and incubated at room temperature (RT) for 30 minutes. The resus-
pended pellet was centrifuged again (15000 x g for 30 minutes at 4°C) to separate the 
solubilized membranes. The pellet containing the SOMPs was washed twice with 
HEPES and resuspended in the same buffer. Total amount of protein was quantified by 
Bradford protein assay.  Prepared SMOPs were used as antigen to determine the anti-
body concentration generated in vaccinated and control animals. Commercially available 
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S. typhimurium LPS (Sigma) was used to determine the antibody concentration against 
this antigen.  
III.2.11 FAST-ELISA 
 
Anti-Tsol18, anti-SOMPs and anti-LPS specific IgG antibodies were quantified by 
FAST-ELISA as previously described (Hancock and Tsang, 1986). Sticks were sensi-
tized with 2 µg/ml of the antigen (LPS, SOMPs or Tsol18) diluted in 0.05M Tris/HCl, 
0.3M KCl, 2.0 mM ethylenediaminetetracetic acid (EDTA) pH 8.0. Mice sera were diluted 
1: 33 in PBS; 0.3% tween 20; 5% nonfat dry milk. Affinity purified rabbit anti mouse IgG 
POD labeled antibody was used as conjugate (Tsang et al., 1995). A standard curve of 
purified mice IgGs was used for quantification. Specific IgG concentration was calculated 
based on the activity of the standard curve. Serum samples with absorbance values ac-
tivities higher than those of the standard curve were further diluted and re-assayed. 
 
III.3 Results 
III.3.1 Vaccine construction and Tsol18 expression 
 
We successfully cloned mature Tsol18 sequence into pYA3620 plasmid and 
transformed into Salmonella χ9402. Colony PCR results confirmed successful transfor-
mation (data not shown). DNA sequence analysis showed there was no mutation in the 
clone. The RASV construction expressing recombinant Tsol18 as detected by western 
blot is shown in Figure III.1 (Tsang et al., 1989) 
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Figure III.1 Recombinant Tsol18 expression by RASV. 
 
 
Whole cell lysate Salmonella Typhimurium X9402 synthesizing bla - SS- Tsol18 
– blaCT fusion protein collected at different time points after inducing with IPTG. (C) 
Vector control harboring the empty plasmid served as control. Tsol18 = purified recom-
binant Tsol18 used as positive control; +, induced; -, uninduced. Arrows indicate pure 
recombinant Tsol18 and the fusion protein in each induced lane. 
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III.3.2 Plasmid stability 
 
Expression of rTsol18 antigen by our RASV construct was accomplished by in-
troducing a recombinant plasmid encoding the Tsol18 gene. Therefore, plasmid stability 
becomes a crucial factor for antigen delivery and for the success of the vaccine system. 
The balanced-lethal system is designed to avoid the use of antibiotic resistance as se-
lective marker. It uses the asd gene of Salmonella enterica serovar Typhimurium was for 
plasmid maintenance (Koji Nakayama, 1988). Plasmid pYA3620 complemented the asd 
mutation of Salmonella host strain χ9402 and was stably maintained for 50 generations 
(data not shown). There was no difference between the LPS profiles of χ9402 (with or 
without the asd+ plasmid) and the wild type strain χ3761 (data not shown). 
 
III.3.3 Humoral immune response in mice 
 
The specific humoral immune response (IgG) induced by the RASV against 
Tsol18, SOMPs and Salmonella typhimurium LPS were quantified by FAST-ELISA in 
both groups of mice. Specific antibodies against Tsol18 were detected as early as day 
14 and showed similar patterns in both groups of immunized mice. Mice immunized with 
a single dose of the vaccine construction (n=7) raised their highest level of antibodies at 
a mean +/- standard error (SE) of 0.78 +/- 0.16 µg/ml on day 42 (Figure III.2). Mice that 
received a booster dose on day 7 (n=8), showed a peak of antibodies against Tsol18 on 
day 28 at a mean +/- SE of 1.26 +/- 0.26µg/ml (Figure III.3). At the end of this experi-
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ment on day 70, the antibody levels were 0.29 +/- 0.07µg/ml and 0.35 +/- 0.4µg/ml in 
animals that received one or two doses, respectively (Figure III.2 and Figure III.3). Both 
groups of vaccinated mice, and the controls showed similar patterns in the specific im-
mune response generated against Salmonella self antigens LPS and SOMPs (Figure 
III.2 and Figure III.3)  
 
 
 
Figure III.2 Specific immune response in vaccinated mice with a single dose of 
RASV. 
 
Mice were immunized with 109 CFU of χ9402/pYA3620-Tsol18 on day 0. 
IgG antibodies to LPS, SOMPs and rTsol18 were measured by FAST-ELISA in 
both; vaccinated and control groups. Data is presented as the mean +/- 2 SE. 
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Figure III.3  Specific immune response in mice vaccinated with two doses of 
RASV. 
 
Mice were immunized twice with 109 CFU of χ9402/pYA3620-Tsol18 on 
days 0 and 7. IgG antibodies to LPS, SOMPs and rTsol18 were measured by 
FAST-ELISA in vaccinated and control groups. Data is presented as the mean 
+/- 2 SE. 
 
III.3.4 Humoral immune response in pigs 
 
Specific IgG immune response against Tsol18 antigen was detected in pigs fol-
lowing the immunization with Salmonella enteric var Typhimurium expressing Tsol18. 
Piglets raised their highest level of antibodies against Tsol18 on day 42 at a mean (+/- 
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SE) of 0.89 +/- 0.05 µg/ml. On this day, the antibody levels against SOMPs and LPS 
were 0.53 +/- 0.05 and 0.41 +/- 0.02 µg/ml, respectively. The highest means of antibody 
concentration against SOMPs an LPS in vaccinated animals were found on day 56 (0.69 
+/- 0.07 µg/ml and 0.56 +/- 0.05, respectively).  The control group also raised their high-
est specific IgG response against Salmonella LPS (0.59 +/- 0.05 µg/ml) and SOMPs 
(0.67 +/- 0.07 µg/ml) on day 56 (Figure III.4). Specific immune response generated 
against Salmonella antigens in animals vaccinated with RASV containing the empty 
plasmid vector was lower than the one generated against Tsol18 in the animals immu-
nized with the construct encoding Tsol18. 
 
Figure III.4 Serum IgG concentration to Salmonella enterica serovar Typhimu-
rium LPS, SOMPs and to rTsol18 in immunized pigs 
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Pigs were orally immunized with 1012 CFU of χ9402/pYA3620-Tsol18 on day 0. 
The control group was immunized with the Salmonella strain harboring the empty plas-
mid. Animals were challenge with one T. solium proglottid on day 30. IgG antibodies to 
LPS, SOMPs and rTsol18 were measured by FAST-ELISA in vaccinated and control 
groups. Data is presented as the mean +/- 2 SE. 
 
III.3.5 Pig challenge 
 
The vaccine trial was carried out in Peru. All piglets were obtained from a cysti-
cercosis free farm located in Lima.  All animals were sacrifice 90 days after challenge 
and the carcasses were inspected for the presence of cysticerci. The median number of 
cysticerci found in vaccinated and challenged pigs is shown in Table III.2. The mean 
numbers of viable and total number of cysts in vaccinated pigs were lower than the 
numbers in the control group and were statistically significant (P< 0.05; Mann – Whitney 
test).  Vaccination with RASV specifying for Tsol18 reduced the number of viable cysts 
with one pig having no viable cysticercus detected. The total number of cysts was also 
significantly reduced.  Evagination percentage was also lower in the vaccinated group 
than in the control. Percentages of evagination ranged from 0 to 60% whereas in the 
control group ranged from 82 to 100%. Clinical observation and clinical exams per-
formed in the experimental animals included body temperature; respiratory frequency; 
feces consistency, appetite; weight and attitude (alert or depress).   Orally immunized 
pigs did not showed any health or development problems during the time of duration of 
the experiment. 
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III.4 Discussion 
 
Vaccination remains one of the most effective tools for managing infectious dis-
eases in human public health and animal production. The rational development of vac-
cines requires an understanding of the physiology of the pathogen (Spreng et al., 2006). 
Ideally, an effective vaccine system should elicit immune responses that result in protec-
tion against challenge. In addition, a vaccine system should also be easily administrated, 
affordable and capable of promoting long lasting protection (Nayak et al., 1998), espe-
cially for diseases in economically challenged countries.  Furthermore, in the context of 
cysticercosis, vaccines that are able to stimulate not only systemic but also mucosal im-
mune responses have the advantage of stimulate local immune responses at the port of 
entry.  In this regard, the use of attenuated bacteria that are unable to cause clinical dis-
ease but trigger a self-limiting infection leading to the stimulation of protective immunity 
represents an attractive alternative (Spreng et al., 2006). 
 
Immunity to the larval infection of Taenia during the early stages of infection is 
primarily antibody mediated (Blundell et al., 1968; Gemmell et al., 1968; Blundell et al., 
1969). Reports have shown that circulating antibodies generated against metabolic 
products of metacestodes during early stages of infection are protective. In the particular 
case of T. solium one of such immunogenic antigens is Tsol18, a metabolic product pro-
duced during the oncosphere stage of the parasite that have been proved to be protec-
tive when used as recombinant antigen (Lightowlers, 2003; Flisser et al., 2004; Gonza-
lez et al., 2005; Gauci et al., 2006; Kyngdon et al., 2006b). The use of RASV strains to 
deliver heterologous antigens has advantages over the use of isolated antigen. One ad-
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vantage is that the production of the recombinant antigen by the bacteria alleviates the 
need for an adjuvant. Another advantage is that there is no need for in vitro production 
or purification of the immunogenic antigen. Finally, the ability of Salmonella to colonize 
the gut lymphoid tissues permits the stimulation of not only mucosal but humoral im-
mune responses (Spreng et al., 2006).  
 
Attenuated Salmonella vaccine strains are able to elicit immune responses 
against antigens that are only expressed in vivo (McGhee et al., 1992). The present 
study demonstrated that the T. solium protective antigen Tsol18 can be expressed in an 
immunogenic in a Salmonella based live vaccine strain. We have cloned mature Tsol18 
gene that codes for a 113 aminoacids protein into a recombinant plasmid that harbored 
the β-lactamase secretion system and transformed into a ∆crp, ∆cya Salmonella enteri-
ca serovar Typhimurium χ9402 strain.  
 
The immune responses to both the heterologous and Salmonella self antigens 
depends on the ability of the RASV to replicate and persist in the host cells. Another im-
portant factor in generating specific immune responses is the stability of the recombinant 
plasmid (Galen and Levine, 2001). Our vaccine construction well tolerated by mice and 
piglets; and was able to induce a specific immune response against Tsol18 in both 
groups of vaccinated animals. Serum from immunized animals with the RASV strain 
reacted with purified Tsol18, suggesting successful delivery of the antigen and induction 
of humoral immune response. The ability of strain χ9402 (pYA3620-Tsol18) to produce 
Tsol18 at immunogenic concentrations was probably an important element of its ability 
to elicit high level of specific IgG response to Tsol18. Higher specific anti Tsol18 IgG was 
61 
found in both, mice and piglets on day 42 after immunization. Specific anti Tsol18 anti-
body concentration decreased rapidly and by day 98 after immunization the antibody 
concentration was 0.19 +/- 0.04 µg/ml (Figure III.2; Figure III.3 and Figure III.4).  Both 
experimental groups of animals showed higher antibody concentration against Tsol18 
than against Salmonella OMPs and LPS (Figure III.2; Figure III.3 and Figure III.4). The 
observation that the anti-LPS and anti-SOMPs IgG concentrations induced by the vac-
cine construction (χ9402/pYA3620-Tsol18) and those generated by the same strain har-
boring empty plasmid in the control groups were comparable indicated that the expres-
sion of Tsol18 did not affect the immunogenic potential of the bacteria.  
 
We also tested the efficacy of the RASV to induce protective immune response 
through a vaccination and challenge trial. Although our trail challenge did not achieve a 
100% of protection in vaccinated animals as it was previously reported with another vac-
cine system (Flisser et al., 2004; Gonzalez et al., 2005), we did significantly reduce (P < 
0.05) the number of healthy cysts in vaccinated animals with a single dose of our RASV. 
Reductions of the amount of viable cysts and in its ability to evaginate are of epidemio-
logical importance as they are the source for human infection (Table III.2). There was 
only one animal with no viable cysts, however; the  healthy cyst found in the other pigs 
during carcasses inspection had their  ability to evaginate reduced to levels ranging from 
0 to 60%.  
  
In conclusion, heterologous expression of Tsol18 a protective antigen against T. 
solium cysticercosis was demonstrated in Salmonella enterica serovar Typhimurium 
χ9402. The balanced-lethal vector used to clone and express the immunogenic protein 
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was stably maintained in the system.  We have also demonstrated the ability of the vac-
cine system to elicit specific IgG response in immunized mice and piglets. Moreover, we 
have demonstrated the ability of the RASV system of delivering protection to pigs using 
a single dose.  Our data together suggest that our RASV is highly effective delivering 
Taenia solium Tsol18 antigen and to induce specific immune response to reduce infec-
tion burdens in infected animals when it is orally administrated in a single dose.  
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IV. CONCLUSIONS 
 
Many immunological aspects of the relationship between Taenia sp. Metaces-
todes and their hosts have been delineated as a result of investigations performed dur-
ing the early 1930’s. From these studies the following principals have been demonstrat-
ed to be applicable to all Taenia metacestodes, including Cysticercus cellulosae: 
 
1. Infection lead to immunity to re-infection (Miller and Gardiner, 1932; Kerr, 1935). 
2. Naïve hosts can be protected by immunization of with metabolic products ob-
tained from non living parasites (Miller and Gardiner, 1932; Campbell, 1936; 
Campbell, 1938b). 
3. Naïve hosts cab by protected by passive transfer of serum from an infective or 
actively immunized animal (Campbell, 1938b; Campbell, 1938a). 
4. During early infections, protection properties of passive transferred serum is as-
sociated with IgG antibodies (Leid and Williams, 1974b; Leid and Williams, 
1974a; Musoke et al., 1975). 
5. Antiparasitic effect on immunized animals have the ability to kill activated oncos-
pheres cultivated in vitro (Kyngdon et al., 2006b). 
 
These principals obtained from early investigations in the immunobiology of Taenia 
infections set the scene for vaccine development. Previous studies have shown that a 
metabolic protein known as Tsol18 produced by the larval stage of Taenia solium is ca-
pable of inducing strong circulating antibodies. Moreover this strong immune response 
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have demonstrate to be protected for vaccinated animals (Flisser et al., 2004; Gonzalez 
et al., 2005). Although this metabolic product have demonstrated to be protective when 
used as recombinant protein, it use have some disadvantages: 
 
- Production and purification of recombinant proteins are expensive and require 
expensive reagents and equipment. 
- Tsol18 used as a recombinant antigen needs to be injected twice into the host in 
order to protect vaccinated animal. Vaccination through injection requires animal 
handling that is not always available under field conditions. 
 
Genetic manipulation of Salmonella species has resulted in the loss of their pa-
thogenicity without interfering with their ability to stimulate the immune system. In this 
regard, attenuated Salmonella has the ability to generate a strong mucosal immune re-
sponse in addition to the humoral and cellular immune responses not only against self 
antigens, but also against recombinant ones (Dougan et al., 1989). Attenuated and im-
munogenic strains of Salmonella can be genetically engineered to stably express foreign 
antigens. Recombinant strains used as vaccine delivery systems, usually have a plasmid 
vector that harbors the sequence for the foreign antigen (Chatfield et al., 1993; Chatfield 
et al., 1994). Several foreign antigens from pathogens closely related to Salmonella and 
also from viruses, or parasites have been expressed in recombinant avirulent Salmonel-
la and tested for safety and efficacy against challenge in animal models. Good immune 
responses were observed when the foreign antigen is retained in the cytoplasm of the 
recombinant Salmonella as well as when foreign antigens are localized to the periplas-
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mic space, or to the outer membrane (Khan et al., 1994; Chabalgoity et al., 1996; Cha-
balgoity et al., 2000; Kang et al., 2002). 
 
The RASV system expressing Tsol18 protective antigen and capable of inducing 
protective antibodies in vaccinated piglets developed in this research bring some advan-
tages over the use of an isolated recombinant antigen as the one described above:  
 
- The use of a bacterial system to deliver the recombinant antigen alleviates the 
need for an adjuvant. 
- Purification of the antigen is no longer required; therefore, production of the vac-
cine becomes cheaper. 
- The ability of the RASV system to colonize the host gut associated lymphoid tis-
sue without producing any disease, permits not only strong stimulation of specific 
humoral immune response but also local immune response at the point of para-
site entry. 
 
The vaccine construction presented in this research was capable of express 
Tsol18 antigen and was stably maintain in Salmonella up to 50 generations. This con-
struction was also capable to of elicit specific humoral immune response not only against 
the recombinant Tsol18 but also against Salmonella self antigens such as SOMPs and 
LPS. Moreover quantification of the specific antibody response by FAST-ELISA showed 
that the amount of antibodies generated against Tsol18 where higher than those gener-
ated against SOMPs or LPS. The efficacy trial performed as a fundamental part of this 
research showed a significant reduction in the numbers of viable cysts present in vacci-
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nated pigs when compared with the control group. Vaccination not only reduced the 
number of viable cysts but also their ability to evaginate.  This reduction in the number of 
viable cysts and in the evagination rates becomes of epidemiological importance as 
healthy cysts are the source of human infection and the way for disease perpetuation. 
 
This work presents 2 important tools that can improve Taenia solium control pro-
grams in field: An effective, feasible, safe, inexpensive and easy to use vaccine system 
for field use and an quantitative, simple, inexpensive and rapid immological test able to 
measure the amount of specific antibodies against Tsol18 generated in vaccinated ani-
mals that can be use as a tool to follow the immune response in vaccinated animals in 
field and determine if they are protected. 
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